middle.news

Racura moves RC220 leukaemia trial towards first patient

8:51am on Wednesday 18th of November, 2026 AEDT • Biotechnology
Read Story

Racura moves RC220 leukaemia trial towards first patient

8:51am on Wednesday 18th of November, 2026 AEDT
Key Points
  • Sheba Medical Center ethics approval for the EMILI Phase 2b/3 AML trial
  • Phase 2b to enrol up to 68 patients and is funded from existing cash
  • Site activation is targeted by the end of 2026, with first patient treatment expected in Q1 2027
  • Phase 3 progression depends on results, funding and regulatory consultation
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Racura Oncology (ASX:RAC)
OPEN ARTICLE